Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

The Lancet Oncology
Michele MaioBRIM8 Investigators

Abstract

Systemic adjuvant treatment might mitigate the high risk of disease recurrence in patients with resected stage IIC-III melanoma. The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAFV600 mutation-positive melanoma. BRIM8 was a phase 3, international, double-blind, randomised, placebo-controlled study that enrolled 498 adults (aged ≥18 years) with histologically confirmed stage IIC-IIIA-IIIB (cohort 1) or stage IIIC (cohort 2) BRAFV600 mutation-positive melanoma that was fully resected. Patients were randomly assigned (1:1) by an interactive voice or web response system to receive twice-daily adjuvant oral vemurafenib 960 mg tablets or matching placebo for 52 weeks (13 × 28-day cycles). Randomisation was done by permuted blocks (block size 6) and was stratified by pathological stage and region in cohort 1 and by region in cohort 2. The investigators, patients, and sponsor were masked to treatment assignment. The primary endpoint was disease-free survival in the intention-to-treat population, evaluated separately in each cohort. Hierarchical analysis of cohort 2 before cohort 1 was prespecified. This trial is registered with ClinicalTrials.gov, number NCT01667419. The study enrolled 184 patien...Continue Reading

Citations

Sep 7, 2018·The British Journal of Dermatology·G BrancaccioG Argenziano
Nov 28, 2018·Journal of Surgical Oncology·Minyoung KwakGeorgia M Beasley
Jan 25, 2019·Current Treatment Options in Oncology·Kenjiro Namikawa, Naoya Yamazaki
Dec 5, 2018·The Journal of Pathology·Roy RabbieCarla D Robles-Espinoza
May 18, 2019·American Society of Clinical Oncology Educational Book·Melinda YushakAndrew Poklepovic
Mar 14, 2018·Nature Reviews. Clinical Oncology·Diana Romero
Mar 22, 2019·Melanoma Research·Stephanie A Blankenstein, Alexander C J van Akkooi
Apr 9, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Daniel G CoitAnita M Engh
Aug 23, 2019·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Markus V Heppt, Carola Berking
Jun 10, 2019·American Journal of Clinical Dermatology·Alessandro A E TestoriMario Mandalà
Nov 27, 2019·Current Oncology Reports·Justine V Cohen, Elizabeth I Buchbinder
Oct 1, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O MichielinUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Mar 15, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Faruk Tas, Kayhan Erturk
Aug 1, 2019·Expert Review of Clinical Pharmacology·Regina KrattingerReinhard Dummer
May 13, 2020·Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Società Italiana Di Dermatologia E Sifilografia·Giuseppe ArgenzianoPiergiacomo Calzavara Pinton
May 14, 2020·The Australasian Journal of Dermatology·Prachi Bhave, Andrew Haydon
Nov 14, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·C LongoG Pellacani
May 14, 2020·Expert Opinion on Investigational Drugs·Laura Amanda BoosJames Larkin
Jul 16, 2020·Expert Review of Anticancer Therapy·Erin McClureJonathan S Zager
Dec 24, 2018·Expert Opinion on Orphan Drugs·Zeynep Eroglu, Alpaslan Ozgun
Aug 16, 2019·Journal of Translational Medicine·Paolo Antonio AsciertoCorrado Caracò
Apr 2, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rahul SethPauline Funchain
Jul 26, 2018·Annals of Surgical Oncology·Andrew J SinnamonGiorgos C Karakousis
Oct 23, 2019·Oxidative Medicine and Cellular Longevity·Dehai XianJianqiao Zhong
Dec 24, 2018·Journal of Surgical Oncology·Joseph G CromptonMary S Brady
Jun 27, 2019·Current Treatment Options in Oncology·Maiko Wada-OhnoMasutaka Furue
Aug 8, 2020·Frontiers in Molecular Biosciences·Enrica Teresa TandaFrancesco Spagnolo
Dec 7, 2019·Melanoma Management·Evangeline SamuelAndrew Haydon
Feb 1, 2020·Current Pharmaceutical Design·Khanh B TranPeter R Shepherd
Apr 3, 2019·International Journal of Molecular Sciences·Paola SavoiaOttavio Cremona
Oct 20, 2020·Frontiers in Cell and Developmental Biology·Cheila BritoMarta Pojo
Oct 22, 2020·Cancers·Martin SalzmannJessica C Hassel
Nov 25, 2020·Annals of Surgical Oncology·Richard J StrakerGiorgos C Karakousis
Aug 28, 2019·Deutsches Ärzteblatt International·Patrick TerheydenThomas Eigentler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Basal Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

© 2022 Meta ULC. All rights reserved